

Combination therapy for glioblastoma shows promising results in early-stage research

25 January 2017, by Reggie Kumar

UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which is specifically intended to treat brain tumors, is called autologous tumor lysate-pulsed dendritic cell vaccination. It uses a portion of the patient's own brain tumor and is currently being tested in humans.

Provided by University of California, Los Angeles

In tests in animals, the scientists found that a combination of the vaccine and two different drugs that modulate distinct aspects of the immune system was more effective at allowing T cells to attack glioblastoma than the vaccine alone. The two added drugs were a PD-1 antibody blockade, which enhanced T cell activation inside the tumor, and an [investigational drug](#) called PLX3397, which reduces [immune suppression](#) within the tumor.

Glioblastoma is the most common type of [malignant brain tumor](#) in adults, and one of the deadliest. More than 12,000 people will be diagnosed with the disease this year, and the five-year survival rate for patients is less than 5 percent. It has a high probability of recurring after treatment and there is no standard therapy for [recurrent glioblastoma](#). The team studied the approach in mice and on tumor samples from human patients.

The findings may point scientists to a process for developing more effective combination treatments for people with glioblastoma and other immunosuppressive cancers.

More information: Joseph P. Antonios et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma, *Neuro-*

APA citation: Combination therapy for glioblastoma shows promising results in early-stage research (2017, January 25) retrieved 20 November 2019 from <https://medicalxpress.com/news/2017-01-combination-therapy-glioblastoma-results-early-stage.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.